Henri Termeer Joins Prosensa as Strategic Advisor
News Dec 14, 2012
Prosensa has appointed industry leader and former Genzyme CEO, Mr. Henri Termeer as Strategic Advisor. His role at Prosensa will be to provide input on the company’s corporate strategy and growth plans.
Commenting on his appointment, Mr. Termeer said: “Prosensa has the key ingredients of a successful company in the rare disease community: breakthrough science, a highly motivated workforce and a passionate commitment to improving the lives of patients. I am very much looking forward to working with the Prosensa team.”
Prosensa’s CEO, Hans Schikan, commented: “We are very pleased that Henri is joining the team as a Strategic Advisor. Under his leadership, Genzyme became a world-leading biotech company and a pioneer in rare diseases and orphan drugs. His expertise will be invaluable to use as we drive our products and technology forward.”
Henri Termeer served as Chairman, President and CEO of Genzyme Corporation for nearly three decades. Under his leadership, the company evolved from a mid-sized biomedical company to one of the world’s leading biopharmaceutical companies, especially in the field of rare diseases and orphan drugs.
He retired from Genzyme in 2011 following its acquisition by Sanofi in a transaction valued at more than $20 billion. Mr. Termer is also involved in a number of other companies and not-for-profit organizations.
Commenting on the appointment, Mr. Daan Ellens, Chairman of Prosensa’s Supervisory Board, said: “Henri is a luminary in the biotech world, and an expert in rare diseases and orphan drugs. His expertise will be crucial in supporting our goal of developing and commercializing oligonucleotide treatments for rare neuromuscular disorders. We welcome him on board.”
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE
Edico Genome and Fabric Genomics Develop Integrated Solution for Genomics AnalysisNews
Industry leaders partner to provide streamlined variant data analysis solution, with the goal of improving clinical care.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE